Celldex Therapeutics, Inc.

CLDX · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.3%

Institutions110.3%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$1.54M	$7.02M	$6.88M	$2.36M	$4.65M	$7.42M	$3.57M	$9.54M	$12.74M	$6.79M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$287.37M	-$195.08M	-$154.54M	-$115.23M	-$71.24M	-$63.35M	-$55.03M	-$156.44M	-$121.53M	-$132.92M
Operating income as a percentage of revenue.	-18599.8%	-2778.9%	-2245.3%	-4889.0%	-1531.8%	-854.1%	-1540.2%	-1640.1%	-953.7%	-1958.7%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$258.80M	-$157.90M	-$141.40M	-$112.30M	-$70.50M	-$59.78M	-$50.88M	-$151.18M	-$93.03M	-$128.53M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.00	$-2.00	$-2.00	$-2.00	$-1.64	$-2.02	$-3.00	$-14.00	$0.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.00	$-2.00	$-2.00	$-2.00	$-1.64	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$28.87M	$28.36M	$34.81M	$29.43M	$39.14M	$43.84M	$11.23M	$24.31M	$40.29M	$42.46M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$582.98M	$792.34M	$465.63M	$352.74M	$444.65M	$235.84M	$122.93M	$155.81M	$315.62M	$383.36M
Everything the company owes — debt, unpaid bills, and other obligations.	$55.82M	$45.34M	$36.46M	$26.53M	$25.18M	$26.48M	$28.91M	$31.75M	$79.25M	$117.93M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$527.16M	$747.00M	$429.17M	$326.20M	$419.48M	$209.36M	$94.03M	$124.06M	$236.37M	$265.43M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$210.90M	-$157.80M	-$107.30M	-$103.70M	-$60.90M	-$40.40M	-$46.41M	-$75.23M	-$99.93M	-$113.04M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$2.71M	$1.92M	$1.82M	$1.83M	$1.25M	$1.55M	$731000	$813000	$1.79M	$2.75M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$213.61M	-$159.72M	-$109.12M	-$105.53M	-$62.15M	-$41.95M	-$47.15M	-$76.05M	-$101.72M	-$115.79M

	You	Peer avg
P/E	–	30.4
Revenue Growth	-97.0%	-11.1%
ROE	-43.9%	-38.3%

Celldex Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison